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Brain-specific regulator of G protein signaling 9 (RGS9-2) is a member of a family of proteins that can function as GTPase-activating
proteins for heterotrimeric G proteins. In the present study, we examined the intracellular distribution of RGS9-2 in native brain tissue and
transfected cells. Immunocytochemical and immunoblot experiments revealed an unexpectedly high proportion of RGS9-2 within the nuclei
of forebrain neurons. A similar intracellular distribution was seen in transfected COS-7 cells. The RGS9 binding partner Gh5 further
enhanced the nuclear localization of RGS9-2, but did not affect the strongly cytoplasmic localization of RGS9-1, the retinal form of RGS9.
Deletion construct analysis revealed that the unique polyproline-rich C-terminus of brain-specific RGS9-2 contains sequences necessary and
sufficient to target RGS9 to the nucleus of COS-7 cells, as well as cultured striatal neurons. Furthermore, RGS9-2 transfection increased the
transcriptional activity of a neuronal gene construct normally expressed in RGS9-positive neurons, suggesting that nuclear RGS9 directly or
indirectly regulates transcription in vivo. The nuclear localization of RGS9-2 suggests a heretofore-unanticipated role for this brain-specific
protein in transducing signals to the nuclei of forebrain neurons.
D 2004 Elsevier B.V. All rights reserved.Keywords: RGS9-2; G protein signaling; GTPase activity1. Introduction
Heterotrimeric G proteins couple the detection of extra-
cellular signals by numerous transmembrane receptors to a
variety of intracellular processes. The activity of G proteins
is limited by the rate of Ga subunit GTP hydrolysis.
Specifically, the intrinsic timing mechanism of Ga subunit
GTP hydrolysis is subject to regulation by a family of
proteins known as regulators of G protein signaling (RGSs).
By accelerating Ga GTPase activity, RGSs act as GTPase-
activating proteins (GAPs) and therefore can profoundly
alter G protein-mediated signal transduction. All of the
approximately 30 RGSs that have been identified contain
the highly conserved RGS domain. However, RGS protein
family members differ in the presence of additional, non-0167-4889/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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signaling partners and also in patterns of tissue-specific
expression [1]. Therefore, the RGSs may be involved in
diverse physiological processes beyond their defining GAP
activity.
One of the larger and more intriguing members of the
RGS family is RGS9. Two distinct proteins are encoded by
the RGS9 gene, RGS9-1 (also termed RGS9-S) and RGS9-2
(also termed RGS9-L). RGS9-1 is abundantly and specifi-
cally expressed in the retina where it functions as a GAP for
transducin, playing a critical role in phototransduction [2–
4]. The brain-specific RGS9-2 isoform arises from alternate
RNA splicing of RGS9 gene transcripts and is expressed
almost exclusively in brain regions innervated by dopamine-
containing neurons (e.g. caudate-putamen, nucleus accum-
bens, neocortex) [5–8]. The highly restricted pattern of
RGS9-2 expression in the forebrain, as RGS9-1 in the
retina, implies cell-specific function(s). It has been reported
that the abundance of RGS9-2 is altered in Parkinson’s
disease [9] and by psychostimulants [10], and that RGS9-2
influences the development of tolerance to morphine
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potential therapeutic target for the modulation of neuronal
function and behavior. Nevertheless, unlike retinal RGS9-1,
the cellular localization and function(s) of RGS9-2 is not
completely understood.
The two RGS9 isoforms belong to the R7 RGS subfam-
ily (comprised of RGS6, RGS7, RGS9 and RGS11) that
contains the N-terminal disheveled/egl10/pleckstrin (DEP)
domain and the G protein g subunit-like (GGL) domain.
Recent studies of RGS9-1 define a role for the DEP domain
in targeting RGS9-1 to the site of its GAP activity [12–15].
The R7 RGS subfamily GGL domain mediates binding of
the RGSs to the Gh subunit Gh5 (for review see Ref. [16]).
This association of Gh5 with the GGL domain contributes to
the nuclear localization of RGS6 [17] and RGS7 [18].
Although RGS9-1 and RGS9-2 share the DEP and GGL
domains, they vary in the carboxy-terminal regions. Retinal
RGS9-1 has a much shorter and dissimilar C-terminus that
is thought to contribute to its cellular localization (i.e. the
plasma membrane) [19], whereas RGS9-2 contains a large
and unique polyproline-rich C-terminus (PRO) domain that
has recently been shown to stabilize the protein structure
and enhance the GAP activity by increasing the binding
affinity of the Ga to RGS9-2. [20]. However, the RGS9-2
PRO domain may have additional functions. In the present
study, we determine the subcellular distribution of native
RGS9-2 in brain and demonstrate that the PRO domain
contributes to the nuclear localization of RGS9-2 in a Gh5-
independent manner. Furthermore, we demonstrate that
RGS9-2 increases the transcriptional activity of a neuronal
gene construct, suggesting a functional role of nuclear
RGS9-2.2. Materials and methods
2.1. DNA constructs
Rat RGS9-2 cDNA, cloned as previously described [5],
was subcloned into the pcDNA6A vector containing a C-
terminus V5 tag (Invitrogen) by PCR using specific primers.
Specific domains of RGS9 were derived by PCR using
5Vsense primers containing BamH1 sites upstream of the
start codon and 3V antisense primers containing a SalI site.
PCR products were purified, digested with BamH1 and SalI,
cloned into pcDNA6A, and sequenced. In the case of RGS-
PRO-EGFP, a 5Vsense T7 primer and a 3Vprimer with a
BamH1 site were used to amplify RGS-PRO for insertion into






GGTCAG (PRO); 5VTAATACGACTCACTATAGGG (RGS-
PRO-EGFP). Antisense RGS9 primers employed were:5VATGTCGACTGTGGCTCGATAGCTTTGGCC (DEP-




EGFP). Full-length RGS-2-EGFP, RGS-1-EGFP, and Gh2
were gifts from Dr. James Granneman (Wayne State Univer-
sity). Plasmids encoding Gh5 (long and short forms) were
obtained from the Guthrie Research Institute. Preprotachyki-
nin A promoter construct  863/ + 449 [21], a gift from Dr.
John Quinn (University of Liverpool), was cloned upstream
of the luciferase reporter sequence in pGL3.
2.2. Cell cultures and transfections
COS-7 cells (ATTC) were maintained in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal calf
serum and transfected with plasmid constructs using a
standard lipofectamine (Invitrogen) method. In some experi-
ments, cells were cotransfected with equimolar amounts of
RGS and Gh constructs. Within 48 h, cells were harvested
for immunoblotting or fixed for immunocytochemistry.
RINm5F cells (ATTC) were maintained in RPMI 1640
medium supplemented with L-glutamine (2 mM), glucose
(2.5 g/l), penicillin/streptomycin, and 10% fetal bovine serum
and transfected using Effectene transfection reagents (Qia-
gen). Dual luciferase transcription assays (Promega) were
performed on cells that had been transfected 40 h previously
with a 10:1 molar ratio of firefly ( 863/ + 449-pGL3) to
Renilla (phRL-TK) luciferase gene constructs, plus different
combinations of RGS9-2, Gh5, or empty pcDNA vector.
2.3. Organotypic striatal cultures and particle-mediated
transfection
Animal use procedures were followed in strict accordance
with the NIH Guide to the Care and Use of Laboratory
Animals and a protocol approved by Wayne State Universi-
ty’s Animal Investigation Committee. Organotypic striatal
slices (300 Am) were prepared from postnatal day 5 male rats
(Sprague Dawley; Hilltop) and transfected by particle-medi-
ated transfection as previously described [22,23], with the
exception that slices were maintained at 33 jC. ‘Bullets’
used for particle-mediated transfection consisted of 1 Am
diameter gold particles prepared using equimolar concen-
trations of RGS9-2 (50 Ag) or RGS-PRO (40 Ag) expression
plasmids.
2.4. RGS9-2 antibody production
A peptide corresponding to the last 15 amino acids of rat
RGS9-2 (EVICPWESLAEGKAG) was chosen for antibody
production based on its immunogenic properties. White
male rabbits were injected twice over a 2-week interval
with KLH-coupled peptide. The specificity of the RGS9-
immunoreactivity was confirmed by Western blotting using
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also by protease digestion.
2.5. Immunohistochemistry and immunocytochemistry
Adult male Sprague Dawley rats were decapitated and
the forebrain caudate-putamen and overlying cingulate cor-
tex were blocked coronally, flash frozen in 2-methylbutane
and stored at  80 jC prior to cryosectioning. Fourteen-
micrometer sections were thaw mounted onto positively
charged slides. Mounted sections were quickly warmed,
dried in a 45 jC slide dryer oven for 10 min, followed by
cold acetone ( 20 jC) fixation for 15 min. Sections were
then air-dried, and endogenous peroxidase suppressed by a
3% H2O2/95% ethanol incubation for 13 min followed by
three washes in phosphate-buffered saline containing 0.25%
Triton X-100 (PBST). Sections were blocked for 1 h at room
temperature in PBST, 5% normal goat serum, 5% normal
donkey serum, and 2% bovine serum albumin, and then
incubated for 1 h at room temperature with primary RGS9-2
polyclonal rabbit antibody (1:1000 final dilution). Sections
were then rinsed three times (30 min each) in PBST,
followed by 1 h incubation with goat anti-rabbit IgG
(H +L; Vector) and 30 min incubation with ABC reagent
(Vector). Following PBST rinses, sections were reacted with
AEC (3-amino-9-ethylcarbazole in N,N-dimethylforma-
mide; Sigma AEC 101) in deionized water along with 3%
hydrogen peroxide. After sufficient staining, sections were
rinsed in deionized water for 10 min. Counterstaining was
achieved with a 5 min incubation with Gill’s hematoxylin
followed by deionized water rinse for 30 min. Sections were
aqueous mounted (Crystal Mount) and coverslipped. Serial
sections were processed with antisera that had been blocked
with a 100-fold molar excess of antigen peptide to confirm
specificity (data not shown).
Expression of RGS9-2 constructs in COS-7 cells was
visualized by immunofluorescence. Two days post-trans-
fection, cells were fixed with methanol at room tempera-
ture for 10 min, then blocked overnight with 2% bovine
serum albumin in phosphate-buffered saline (BSA/PBS).
Samples were then incubated at 4 jC overnight with
mouse monoclonal anti-V5 antibody (Invitrogen; 1:500
dilution), rabbit anti-Gh5 antibody (gift of Dr. Bill
Simonds, NIH; 1:500 dilution), or rabbit anti-EGFP anti-
body (Molecular Probes, 1:1000 dilution). After several
washes, cells were incubated for 1 h at room temperature
with Cy2- or Cy3-conjugated goat anti-mouse or anti-
rabbit IgG (Jackson Immunoresearch, 1:400 dilution for
Cy2 and 1:500 dilution for Cy3) then thoroughly rinsed
prior to analysis of fluorescence. In some experiments, cell
nuclei were visualized following a 30-min 37 jC incuba-
tion with SYTOXR Green (Molecular Probes). Fluores-
cence was imaged using a Zeiss Axioskop equipped with
AttoArc 2 Fluorescence capabilities, a SPOT RT digital
camera (Diagnostic Instruments), and Image-Pro Plus soft-
ware (Media Cybernetics).For immunocytochemical analysis of transfected organo-
typic slice cultures, slices were incubated sequentially with
mouse anti-dopamine- and cyclic AMP-regulated phospo-
protein-32 (DARPP) antibody (BD Biosciences; 1:1000
dilution; overnight at 4 jC), followed by Cy3-labeled goat
anti-mouse IgG (Jackson Immunoresearch, as above; 2 h,
room temperature), rabbit anti-EGFP antibody (Molecular
Probes, as above; overnight at 4 jC) and Cy2-labeled goat
anti-rabbit (Jackson Immunoresearch, 1:500; 2 h, room
temperature). For the analysis of these 300-Am-thick slices,
Cy-2 and Cy-3 fluorescence were imaged with an Olympus
Fluoview laser scanning confocal microscope equipped with
argon and krypton lasers.
2.6. Cell fractionation and immunoblotting
Subcellular fractionation was performed as described
by Chatterjee and Fisher [24]. Rat brain regions or
transfected COS-cells were placed in 1 ml of hypotonic
lysis buffer (5 mM Tris, pH 7.4, 1 mM EDTA, 1 mM
EGTA, 10 mM KCl, 2 mM MgCl2, 1 mM dithiothreitol,
and a protease inhibitor cocktail for tissue extracts
(AEBSF, pepstatinA, E-64, leupeptin and aprotinin; Sig-
ma). Tissues or cells were homogenized with a dounce
(15 strokes) and triturated through a 22-gauge needle.
Each homogenate was layered over 0.5 ml of 1.1 M
sucrose-containing lysis buffer and centrifuged for 10 min
at 1500 g at 4 jC. The supernatant (cytoplasmic
fraction) was removed and the pellet gently resuspended
in 0.5 ml of buffer and centrifuged again. The resulting
pellet (nuclear fraction) was resuspended. Whole homo-
genates, cytoplasmic fractions and nuclear fractions were
analyzed by Western blotting. Proteins were electrophor-
esed using Nupage 10% Bis-Tris gel (Invitrogen) then
blotted onto nitrocellulose membranes (BioRad). Mem-
branes were blocked overnight at 4 jC with 5% nonfat
dry milk prior to 1 h incubation at room temperature
with mouse monoclonal anti-V5 antibody (described
above; 1:5000), rabbit anti-RGS9-2 antibody (described
above; 1:1000), goat anti-RGS9 antibody (directed against
the RGS9 N-terminal region; 1:300 (T19, Santa Cruz)),
or mouse monoclonal anti-tyrosine hydroxylase antibody
(1:30,000; gift of Dr. Greg Kapatos, Wayne State Uni-
versity). Membranes were then incubated with horserad-
ish peroxidase (HRP)-conjugated secondary antibody (1:
15,000 goat anti-rabbit (Jackson), 1:10,000 goat anti-
mouse (Jackson), or 1:15,000 rabbit anti-goat (Sigma))
for 1 h at room temperature. Signal was detected using a
chemiluminescence substrate (Perkin Elmer). To confirm
signal specificity, RGS9 antibody was preabsorbed for 2
h with a 100-fold molar excess of blocking peptide
(Santa Cruz) in a small volume of PBS prior to further
dilution and use. As another proof of specificity, rat
striatal and cortical homogenates were digested with the
SDS-resistant V8 protease (Sigma) and Western blots
performed with anti-RGS9 (T19; Santa Cruz Biotechnol-
Fig. 1. Immunohistochemical analysis of endogenous RGS9-2 in forebrain
neurons. Immunohistochemical analysis of rat brain sections (A, striatum;
B, cortex) was performed as described in Materials and methods.
Arrowheads indicate cells with RGS9-2-immunoreactivity seen throughout
the entire cell body, while the arrow indicates a cell with immunoreactivity
largely confined to the nucleus. Scale bar is 10 AM. (C) RGS9-2
immunoreactivity is detected by Western blot in cortex, striatum and RGS9-
2-transfected COS-7 cells with this C-terminally directed, RGS9-2-selective
antibody.
Fig. 2. Subcellular distribution of endogenous RGS9-2 in brain. Rat brain
tissue was fractionated into nuclear and cytoplasmic fractions and subjected
to immunoblotting as described in Materials and methods. Whole
homogenates (WHOLE, lanes 1–3), cytoplasmic fractions (CYTO, lanes
4–6) and nuclear fractions (NUC, lanes 7–9) from cerebral cortex (CTX),
striatum (STR) and liver (LIV) were analyzed for RGS9-2 and tyrosine
hydroxylase (TH) immunoreactivity. RGS9-2-transfected and untransfected
COS-7 cells (TR and UN, lanes 10–11) were used to confirm the nature of
the RGS9-2-immunoreactivity.
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described above. Identical RGS9-2 digested products
were obtained in striatum and cortex (data not shown).
2.7. Statistics
Group comparisons were made by one-way analysis of
variance followed by Tukey–Kramer multiple comparisons
post hoc tests, with P < 0.05 considered significantly
different.3. Results
3.1. Subcellular localization of RGS9 in brain
In initial experiments, the subcellular localization of
RGS9-2 was examined in the rat striatum (Fig. 1A) and
cerebral cortex (Fig. 1B) by immunohistochemistry and
immunoblots (Fig. 1C), using an antibody directed specif-
ically against the C-terminus of RGS9-2. Analysis of striatal
and cortical tissue revealed that in some neurons, RGS9-
immunoreactivity was confined largely to the nucleus, while
in other cells, RGS9-immunoreactivity was observed
throughout the entire soma.
In addition to the RGS9-2 C-terminus specific anti-
body described above, cortical and striatal extracts were
fractionated and Western blots were performed using a
commercially available RGS9 antibody directed against
the N-terminal DEP domain. As seen in Fig. 2, RGS9-2
(a single band of f 82 kDa) was abundantly expressed
in whole cell extracts from cortex and striatum but not
liver (lanes 1–3), as previously reported [5,8]. Surpris-
ingly, the abundance of RGS9-2 in the cortex was similar
to its abundance in the striatum (Fig. 2, lanes 1–2) and
in both brain regions was found nearly equally in both
the cytosolic and nuclear fractions (lanes 4–5 and 7–8).
To confirm the specificities of both antibodies, cortical
and striatal homogenates were digested with the SDS-
resistant V8 protease (see Materials and methods). Iden-
tical digested bands were detected with either of the two
antibodies validating the unexpected cortical and nuclear
localization of RGS9-2. In addition, fractionation of
whole cell extracts was verified by probing blots for
the striatal cytosolic and membrane-associated protein
tyrosine hydroxylase (TH; Fig. 2, lanes 2,5,8), which
was absent in the nuclear fraction. Blots were also
probed to detect the cytoplasmic protein dopamine- and
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the same result (data not shown). These data demonstrate
that brain-specific RGS9-2 is clearly distributed between
the cytoplasmic and nuclear compartments of RGS9-2-
expressing neurons (Figs. 1 and 2) in contrast to the
plasma membrane association of retinal RGS9-1
[13,19,25].Fig. 3. Nuclear localization of RGS9-2 in transfected COS-7 cells. COS-7
cells were transfected with full-length V5-tagged RGS9-2 and analyzed by
immunofluorescence and immunoblotting as described in Materials and
methods. (A) RGS9-2 immunofluorescence. (B) SYTOX Green staining of
nuclei. (C) Overlay of A and B. Arrowheads denote cells with nuclear and
cytoplasmic RGS9, while the arrow denotes a cell with predominantly
nuclear RGS9. (D) Confirmation by immunoblotting of the cytoplasmic and
nuclear distribution of RGS9-2 in RGS9-transfected COS-7 cells.
Fig. 4. The effects of Gh5 on intracellular distribution of RGS9-2. COS-7
cells were transfected with full-length RGS9-2 alone or with a Gh subunit,
then analyzed by immunofluorescence and immunoblotting as described in
Materials and methods. (A) RGS9-2 protein (shown by both immunoflu-
orescence and immunoblotting) was distributed between cytoplasmic and
nuclear compartments. (B and C) Cotransfection with either Gh5S (B) or
Gh5L (C) increased nuclear localization of RGS9-2. Upper right insets in B
and C illustrate robust expression of Gh5 subunits in these cells. (D)
Cotransfection with Gh2 did not alter RGS9 distribution.
t Biophysica Acta 1691 (2004) 141–1503.2. The subcellular distribution of RGS9-2 in brain is
recapitulated in transfected COS-7 cells
To begin to understand the determinants of RGS9-2
cellular localization, we employed a cell culture model
involving transfection of COS-7 cells with a construct
encoding V5-tagged full-length RGS9-2. RGS9 was subse-
quently visualized with an anti-V5 primary antibody and a
Cy3-conjugated secondary antibody (Fig. 3A) while cell
nuclei were labeled using SYTOX Green nucleic acid stain
(Fig. 3B). Image overlay facilitated the visualization of
RGS9 in nuclear versus cytoplasmic compartments (Fig.
3C). As can be seen in Fig. 3, RGS9 was widely distributed
in both the cytoplasmic and nuclear compartments of many
transfected cells, while in other cells, RGS9 was predomi-
nantly nuclear in localization. In parallel, other RGS9-
transfected COS-7 cells were used for subcellular fraction-
ation and immunoblotting experiments. As expected, RGS9
was distributed between nuclear and cytoplasmic fractions
derived from transfected COS-7 cells (Fig. 3D). Thus the
intracellular localization of RGS9 seen in the brain in vivo
was recapitulated in transfected COS-7 cells (compare Fig.
3 with Figs. 1 and 2), facilitating our subsequent investiga-
tion of the domains involved in the nuclear localization of
RGS9.
3.3. The role of Gh5 isoforms in determining the
intracellular distribution of RGS9
The differential distribution of brain versus retinal RGS9
could be related to the tissue-specific isoforms of Gh5 with
which they interact in vivo. Although COS-7 cells normally
express low levels of the brain-specific Gh5S [26], the brain
and retinal forms of Gh5 were compared. RGS9-2 plus Gh5S
(the brain isoform) or Gh5L (the retinal isoform) were
overexpressed in COS-7 cells. Negative controls were
performed by transfecting Gh2 or empty vector in parallel
cultures. Transfected cell cultures were analyzed by immu-
nocytochemistry and Western blotting. As shown in previ-
ous figures, full-length RGS9-2 was expressed in both the
nucleus and the cytoplasm of transfected COS-7 cells (Fig.
4A). Cotransfection of cells with RGS9-2 and either Gh5
isoform resulted in a more prominent nuclear localization of
RGS9-2 (Fig. 4B and C), but not RGS9-1 (data not shown).
The effects of Gh5 on the intracellular distribution of RGS9
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Schematic representation of RGS9-2 and RGS9-1, with their unique C-
termini, as well as RGS9 constructs without either C-terminus or
encompassing only the RGS-PRO domains. In B–E, COS-7 cells were
transfected with one of the four constructs depicted in A, then analyzed by
immunofluorescence and immunoblotting as described in Materials and
methods. (B and C) RGS9-2 protein was distributed between cytoplasmic
and nuclear compartments (B), while RGS9-1 was nearly exclusively
cytoplasmic (C). (D and E) The subcellular distribution of DEP-GGL-RGS
construct was also predominantly cytoplasmic (D), while the RGS-PRO
was found exclusively in the nucleus (E).
Fig. 6. Subcellular localization of RGS9 and RGS-PRO in transfected
striatal neurons. Striatal neurons in organotypic culture were biolistically
transfected with full-length RGS9-2 (left column) or RGS-PRO (right
column) then analyzed for immunofluorescence by confocal microscopy as
described in Materials and methods. All images are a single optical section
(0.5 AM) through the neurons. Panels A and C were generated from a single
scan utilizing argon and krypton lasers, as were panels B and D. A second
scan generated panels G and H. (A and B) Cellular distribution of EGFP-
tagged RGS9-2 and RGS-PRO (seen as green). (C and D) Subcellular
distribution of the marker of striatal medium spiny neurons and cytoplasmic
protein DARPP-32 (seen as red). (E and F) Overlay of the preceding images
reveals the nuclear (green) and cytosolic (yellow-orange) localization of
full-length RGS9-2, while RGS-PRO is seen exclusively in the nucleus
(green) but not the surrounding cytoplasm (which remains red in the
absence of GFP label). (G and H) Merged images of GFP and a
transmission scan of the neurons, with arrows indicating the gold
microbeads within transfected neurons. Scale bars shown.
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GGL domain of RGS9, because Gh2, which does not bind to
the GGL domain, had no influence on the nuclear abun-
dance of RGS9 (Fig. 4D). Gh5 isoforms and Gh2 were
expressed at similar abundances (see Fig. 4B–D, insets). In
summary, both the retinal and brain isoforms of Gh5
increased the relative abundance of nuclear RGS9-2. These
data suggest that Gh5 may contribute to the differential
subcellular distribution of RGS9-2 versus RGS9-1 observed
in vivo.
3.4. The role of the distinct RGS9 C-termini in determining
the intracellular distribution of RGS9 isoforms
We next examined the role of the distinct C-termini of
RGS9-1 or RGS9-2 (see Fig. 5A, schematic) in determin-
ing the intracellular distribution of these RGS9 isoforms.
As before, transfected COS-7 cells showed nuclear and
cytoplasmic distribution of the brain isoform RGS9-2 (Fig.
5B). In contrast, under identical experimental procedures,
retinal RGS9-1 was localized within the cytoplasm, but not
in the nucleus, by immunocytochemistry or immunoblot-
ting (Fig. 5C).
The lack of nuclear RGS9-1 could be due to C-terminus
sequences unique to RGS9-1 (but not RGS9-2) that prevent
nuclear localization or, conversely, to the absence in RGS9-
1 of RGS9-2 C-terminus sequence that promotes nuclear
localization (Fig. 5A). To distinguish between these possi-
bilities, we expressed a construct encompassing the com-
mon DEP, GGL and RGS domains, but lacking the C-
terminal sequence of either RGS9 isoform (Fig. 5A). As
shown in Fig. 5D, the C-terminal truncated version of RGS9
(DEP-GGL-RGS) was localized primarily to the cytoplas-
mic compartment of the cell, with less expression in the
nucleus in contrast to full-length RGS9-2 (see Fig. 5B). As
with RGS9-1, cotransfection with either Gh5 isoform did not
increase nuclear localization of DEP-GGL-RGS (data not
shown). Transfections were also performed with an RGS-
PRO construct (Fig. 5A). The inclusion of PRO sequence
alone was sufficient to strongly target the RGS domain of
RGS9 to the nucleus (Fig. 5E). In separate experiments, it
was determined that constructs encompassing the PRO and
RGS domains in isolation were expressed almost exclusive-
ly in the nucleus and cytoplasm, respectively (data not
shown). Taken together, these data strongly suggest that
the nuclear localization of RGS9-2 is mediated by sequen-
ces within its unique polyproline-containing C-terminus.
To examine the relevance of this PRO sequence to
targeting within authentic CNS neurons, we transfected
organotypic striatal cultures with EGFP-labeled full-length
RGS9-2 or RGS-PRO using particle-mediated transfection,
then optically sectioned the transfected neurons within these
slices using confocal microscopy. Both the RGS9-2 and
RGS-PRO constructs were expressed within striatal neurons
(seen as green labeling; Fig. 6A and B, respectively). The
cytoplasmic compartment of medium spiny striatal neuronswas visualized using an antibody directed against the
cytoplasmic protein DARPP-32, a phenotypic marker for
these cells (seen as red; Fig. 6C and D). The overlay of these
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cytosolic (yellow-orange) localization of full-length RGS9-
2 (Fig. 6E). However, RGS-PRO is seen exclusively in the
nucleus (green) but not in the surrounding cytoplasm (which
remains red in the absence of GFP label; Fig. 6F). The
nuclear plus cytoplasmic localization of RGS9-2 but exclu-
sively nuclear localization of RGS-PRO in transfected
neurons is consistent with the subcellular localization seen
in vivo and in transfected COS-7 cells (Figs. 1–5).
3.5. Functional effect of nuclear RGS9
To begin to address the potential functional effect(s) of
nuclear RGS9-2, the effect of RGS9-2 transfection on the
transcriptional activity of a neuronal gene construct, namely
the preprotachykinin A (PPT) promoter driving luciferase
expression [21] was examined. This gene construct was
chosen because endogenous RGS9-2 and PPT are co-
expressed in the same striatal medium spiny neurons in vivo
[5]. PPT-expressing RINm5F cells [21,27] were cotrans-
fected with PPT-luciferase and RGS9-2 alone or in combi-
nation with Gh5 (Fig. 7). RGS9-2 significantly increased the
transcriptional activity of the PPT-luciferase with or without
Gh5. Cotransfection of PPT-luciferase with Gh5 alone, which
like RGS9-2 exhibits a strong nuclear localization (Fig. 4),
did not alter PPT transcriptional activity (Fig. 7). Importantly,
thymidine kinase promoter activity (used to correct for
transfection efficiency in each sample; see Materials and
methods) was completely unaffected by RGS9-2 transfection
(control: 100F 6%, Gh5: 98F 8%, RGS9/Gh5: 95F 7%,
RGS9: 101F 5%; P < 0.9166). These data argue against
an effect of RGS9-2 on general transcriptional machinery
and provide evidence for the specificity of the effect on
PPT-luciferase activity. These findings suggest that nuclear
RGS9-2 may directly or indirectly alter transcription in
vivo.Fig. 7. The effect of RGS9-2 transfection on the transcriptional activity of a
neuronal gene construct. Preprotachykinin (PPT)-expressing RINm5F cells
were transfected with a PPT-luciferase construct and transcriptional assays
were performed as described in Materials and methods. Cotransfection with
RGS9-2, either alone or in combination with Gh5, significantly increased
(*P < 0.001) transcriptional activity of this neuronal gene construct
compared to transfection with empty vector, whereas cotransfection with
Gh5 alone was without effect. N = 3–6 determinations per group.4. Discussion
Mammalian RGS9 gene expression is highly restricted;
in fact, only retinal photoreceptors and dopamine-innervated
forebrain neurons synthesize RGS9 protein in abundance.
As a result of alternative RNA splicing, the retina and brain
express RGS9 isoforms (RGS9-1 and RGS9-2, respective-
ly). Our study unexpectedly revealed the presence of RGS9-
2 protein in the cortex with two different antibodies, one
directed against the C-terminus and one directed against the
N-terminus. While this manuscript was under review, robust
cortical expression has been reported by the Gene Expres-
sion Nervous System Atlas (GENSAT) study, in which
RGS9 expression was detected in the cortex in postnatal
as well as adult rats [28].
Furthermore, we found that a significant proportion of
the brain-specific RGS9-2 is localized in the nuclei of
forebrain neurons in vivo (Figs. 1 and 2). The prominent
nuclear localization of striatal RGS9 may explain, in part,
the inability to detect RGS9 protein in the nerve terminals of
these striatal projection neurons (Ref. [6]; Bouhamdan, M.
and Bannon, M.J., unpublished data). Transfection experi-
ments demonstrated that a critical determinant of the sub-
cellular localization of RGS9 was the presence (in RGS9-2)
or absence (in RGS9-1) of the 200 amino acid proline-rich
(PRO) domain. The inclusion of the PRO domain was
sufficient to target the RGS domain of RGS9 to the nucleus
of both COS-7 cells (Figs. 3 and 5) and striatal neurons in
organotypic culture (Fig. 6). Cell-to-cell variation in the
subcellular localization of RGS9-2 in both forebrain neurons
(Fig. 2) and transfected cells (Figs. 3–5) suggests that
localization may be subject to dynamic regulation.
Other RGSs show some nuclear localization in transient-
ly transfected cell lines, and it has been suggested that these
RGSs may contain a nuclear localization signal (NLS)
within the RGS domain (for review, see Ref. [29]). RGS9-
2 lacks a readily identifiable NLS in either the RGS or PRO
domain. We have mutated several potential NLS-like
sequences in RGS-PRO (501RK!GN; 503PXP!AXA;
512RR!GG or deleted amino acids 619–677) without
affecting the nuclear targeting of this construct (data not
shown). Additionally, there is no consensus nuclear export
signal, and we have found that the inhibition of nuclear
protein export with leptomycin B does not affect the
intracellular distribution of RGS9-2 (data not shown). The
precise molecular determinants of nuclear targeting of
RGS9-2 thus remain unknown at present. It is conceivable
that the nuclear transport of RGS9-2 is mediated through
interactions with (as yet unidentified) binding partner(s). We
are currently conducting experiments to identify candidate
proteins.
To our knowledge, RGS9-2 (present study) and RGS7
[18] are the only RGSs localized to the nuclei of authentic
CNS neurons. Both of these RGSs form tight complexes
with Gh5 via their GGL domains [16]. Among all Gh
subunits, Gh5 alone seems to be able to augment the nuclear
M. Bouhamdan et al. / Biochimica et Biophysica Acta 1691 (2004) 141–150 149localization of RGS9-2 and RGS7 (present study; Ref. [18]).
Nuclear compartmentalization may provide a reserve of
RGS9-2 that can be readily mobilized to the cytoplasm,
without the need for de novo synthesis. It is also plausible
that Gh5/RGS heterodimers constitute novel signaling sub-
units distinct in localization and function from traditional
Ghg subunits [16,30].
The function of the unique PRO domain of RGS9-2
remains elusive, although a recent study suggests that the
PRO domain allows for a high affinity interaction between
RGS9-2 and Ga [20]. Alternatively, the proline-rich (SH3-
like) motif within RGS9-2 (PPSPSSPFSPSCRPRKPFPSP)
exhibits homology to a number of transcription-related
factors (e.g. transcription initiation factor TFIID 70 kDa
subunit, transcription termination factor-I interacting pro-
tein 5, E1A binding protein p400) and protein tyrosine
kinase 2. In our study, the PRO domain targets RGS9-2 to
the nucleus, where it may directly or indirectly regulate
gene transcription. The data shown in Fig. 7 suggest that
RGS9-2 can enhance the transcriptional activity of a neural
promoter expressed endogenously in RGS9-expressing
forebrain neurons. Recently, several examples of plasma
membrane-associated proteins that directly link G protein
signaling and gene expression have been described
[31,32]. While speculative, it is possible that RGS9-2
provides such a direct link between transmembrane sig-
naling and the regulation of phenotypic genes (such as
PPT) specific to the RGS9-rich neurons of the striatum and
neocortex.
A recent report suggests that the abundance of striatal
RGS9-2 is increased in Parkinson’s disease [9], a disorder
characterized by the loss of dopamine stimulation of D1 and
D2 dopamine receptors. Since RGS9-2 has been shown to
diminish D2 (but not D1) signaling [5], upregulation of
RGS9-2 in Parkinson’s disease might cause an imbalance
between D1 and D2 signaling, and could be related to
progression of the disease and/or the observed loss of
responsiveness to dopamine agonists over time [9]. RGS9-
2 also exerts an important influence over the development of
tolerance to opioids such as h-endorphin and morphine.
Experimental knock down of RGS9-2 expression in mice
increases opioid antinociception and prevents the develop-
ment of tolerance after chronic opioid administration,
strongly suggesting that RGS9-2 normally facilitates toler-
ance to opioids [8]. RGS9-2 also modulates the behavioral
response to cocaine [33]. Taken together, these provocative
data suggest that, with a clearer understanding of its
signaling properties, RGS9-2 may constitute an important
therapeutic target for a number of CNS disorders.Acknowledgements
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